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Evidence-based medicine (EBM) is a rapidly expanding subject, the aim of this editorial is to give an 
overview and address some of the practical issues relevant to the developing world.   
EBM may be defined as the conscientious, explicit and judicious use of current best evidence in 
making decisions about the care of individual patients1.   
 
Abu bakr Alrazi said “ ء وEFGHا JKLـN OPQأ ES Tه
VـWXـYZ[ا J\]س و أ^ـEـK`[ا JKLـN ]ـab”2. This is the 
earliest evedence of EBM we have. However, 
medicine, since the introduction of the basic 
sciences in the discipline based medical curricula 
on 1871 has adopted scientific methodology. With 
the globalization, revolution of information 
technology, the expansion of medical knowledge, 
industry and innovations in the diagnostic and 
treatment modalities, the need for new standards 
and benchmarks emerged to keep in pace. Hence, 
EBM which first appeared in the medical 
literature under this precise terminology in 1992 
by Guyatt et al. 3. The conceptual work which had 
led to that could be traced to the work of 
Professor Archie Cochrane in1972 and to the shift 
in the research methodology launched by the 
introduction of large multicenteric international 
trials in the late eighties of the last century 4, 
which paved  the way for accepting the concepts 
behind evidence-based practice. 
 EBM became a recognized practice with its 
scientific context and methodology. Three areas 
of interest and five steps are necessary for 
practicing EBM 5.  
  
Area 1: Establishing the evidence and 
expressing that in standard terminology:  
          a- Level of evidence  
          b- Level of recommendation  
 To determine that three steps are mandatory: 
         Step 1: Converting the need for information 
(causation, diagnosis,   prognosis, therapy, 
prevention… etc) into an answerable questions. 
Step 2: Tracking down the best evidence to 
answer these questions. 
        Step 3: Critically appraising that evidence for 
its validity (closeness to the truth), impact (size of 
the effect), and applicability (usefulness in our 
clinical practice). 
 
Area 11: Guidelines and managing individual 
patients 
       Step 4: Integrating the critical appraisal with 
our clinical expertise and with our patient's unique 
biology, values and circumstances. This is 
important for setting the guidelines and the best 
plans for individual patients (which will also be 
influenced by the available resources).  
 
Area 111: Promotion of EBM 
      Step 5: Evaluating our effectiveness and 
efficiency in executing steps1-4 and seeking ways 
to improve them both for next time and promoting 
EBM.   
         By setting the standard of classes of 
recommendations and levels of evidence the 
following reforms in the clinical research and 
trials may be noted: 
a- The shift in the study design to meet the best 
level of evidence and to pass the critical 
appraisal 1. 
b- The working groups and societies in almost all 
disciplines of medicine with their continuous 
medical education programs, journals, 
websites, conferences, annual meetings and 
training courses…ect, mastered the drive of 
the clinical trials by a comprehensive approach 
to the pertinent clinical problems and 
transformed them into questions and designed 
the best study to give the best answer.  
c- The collaboration between these working 
groups and medical industries lessen the 
conflict of interest6 and convert the medical 
industries from sellers to promoters and 
developers of medical research with more 
transparency and ethical practice.  
d- The critical appraisal led to a better 
understanding of the level of evidence and 
recommendation acceptance (table).  
The level of evidence ranked from case 
report and expert opinion to multiple large 
randomized double blind-controlled trials with 
more qualifying standards for study design. New 
concepts and definitions emerged to qualify the 
impact of evidence1.  
Based on EBM some of the ideal criteria for 
a given procedure/treatment to be highly 
recommended are: 
1- To have a significant absolute risk reduction 
(ARR): the difference in the absolute risk (rates of 
adverse events) between study and control 
populations1. 
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     Table: Classes of recommendations and levels of evidence of the European Cardiac Society 
 
Recommendations for various tests and procedures are ranked in three classes 
Class 1 Evidence and/or  general agreement that a given diagnostic 
procedure/treatment is beneficial, useful and effective 
Class 11 Conflicting evidence and/or a divergence of opinion about the 
usefulness/efficacy 
Class11a Weight of evidence/opinion is in favour of usefulness/efficacy 
Class11b Usefulness/efficacy is less well established by evidence/opinion 
Class 111* Evidence or general agreement that the treatment is not useful / 
effective and in some cases may be harmful. 
 
The level of evidence related to a particular diagnostic or treatment opinion depends on the 
available data 
Level of evidence A Data derived from multiple randomized clinical trials or meta-
analyses 
Level of evidence B Data derived from a single randomized trial or large non 
randomized studies 
Level of evidence C Consensus of opinion and/or small studies, retrospective studies or 
registries. 
 
*Use of class 111 is discharged unless to alert the medical practitioner for the common 
unsupported mistakes in practice 
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2- If the number needed to treat (NNT) is small: 
the number of patients who must be    exposed to 
an intervention before the clinical outcome of 
interest occurred; for example, the number of 
patients needed to treat to prevent one adverse 
outcome, calculated as the inverse of the absolute 
risk reduction7.  
3- To be safe, with low complications or side 
effects (risk- benefit analysis). 
4- To be cost effective 
          The recommendation will have more 
influence on the guidelines to be applied in 
practice if the condition is of high incidence / 
prevalence and or has a high mortality / morbidity. 
The following scenario may clarify these 
concepts:   
If a condition of a high frequency (e.g. 1000 
cases per month) and has a mortality of 10 %. If 
the recommended procedure decreased the 
mortality to 8%, the ARR will be 2%. So in a 
month, if left untreated 100 patients will die but if 
all the patients are treated, 8o patients will die and 
20 will be saved (20 out of 1000 i.e. 1 per 50 
patients treated) with NNT of 50 but if the 
mortality was reduced to 5% (with ARR of 5%) 
only 50 patients will die and 50 will be saved i.e. 
(1 per 20 patients treated) with NNT of 20, so a 
highly significant effect will result in a high ARR 
and a small NNT.  
The NNT is not an absolute, e.g. in the 
above mentioned example if the procedure is 
highly effective and reduced the mortality to 
almost zero (0.000001%), the100 patients who will 
die if the procedure was not done to them, will all 
be saved (1 patient  per 10 treated) with NNT of 
10, which is the best figure can be attained in this 
case.   
Obviously in this example because the 
condition is of high incidence and mortality, still  
the procedure  with ARR of 2% and NNT of 50 
will be recommended but will provoke research 
questions for a more effective procedure with a 
resultant NNT approaching 10.   
       In the era of outcome based medical education 
and quality assurance, life is getting more 
demanding e.g. in the past we might have tested 
the effect and safety of a drug but now more end 
points are expected such as the risk reduction and 
long term effects on mortality, morbidity and 
quality of life, so we need to integrate the critical 
appraisal with our clinical expertise and with our 
patient's unique biology, values and circumstances. 
  Generally with EBM there is a conceptual shift 
from: 
1- The competence of individual consultants and 
doctors to team work, policies and guidelines. 
2- Competition to cooperation (win for others to 
win). 
3- Effect to impact and outcome (better patient 
care). 
4- Isolated medical to a multidisciplinary set up of 
practice and care. 
 
The limitations of available evidence may 
include: 
1-Not all evidence is made accessible 
(publication bias).  
2- Failure to publish negative trials (conflicts 
of interest)6. 
3-Treatment effectiveness reported from 
clinical studies may be higher than that 
achieved in later routine clinical practice due 
to the closer patient monitoring during trials 
that leads to much higher compliance rates.  
The main criticism for evidence-based 
medicine may be summarized as follows8:  
1- Lack of evidence and lack of benefit are 
not the same.   
2- EBM applies to populations, not 
necessarily to individuals.  
3- Although EBM is quickly becoming the 
"gold standard" for clinical practice and treatment 
guidelines, but most current medical and surgical 
practices do not have a strong literature base 
supporting them5, this may be attributed to many 
reasons e.g. in open-heart surgery, conducting 
randomized controlled trials would be unethical 
and here it may be reasonable to accept the best 
attainable level of evidence e.g. Level B – non 
randomized trial. On the other hand certain groups 
have been historically under-researched (women, 
racial minorities, people with many co-morbid 
diseases), and thus the literature is sparse in areas 
that do not allow for generalizability5.  
 
       The developing countries are scarcely part of 
the multi-center randomized trials which are the 
source of high level of evidence. However, at least 
we need to establish our local data and to see if 
they are conforming to the international 
recommendations and guidelines. 
      The real impact may come from the reforms of 
the set up of practice to enable the application of 
the recommendations as this in the developed 
world may mean slight adjustments but for the 
developing world it may imply a comprehensive 
revision of the health system and the auxiliary 
services  
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One of the positive moves is the projects of 
combating the endemic diseases such as the 
control of tuberculosis and the eradication of 
leprosy which are designed in collaboration 
between the local health authorities, WHO and the 
NGOs and adopting an integrated, comprehensive 
and nationwide approach,  with good auditing and 
reporting system. With such practice these projects 
will match the criteria for good levels of evidence 
and will be the source of new recommendations to 
improve the current practice.  
 
Conclusion and future trends: 
To improve the application of EBM, there may be 
a need for: 
1- Promotion and dissemination of the concepts 
and values of EBM  
2- Making use of the EBM atmosphere to improve 
the set up of practice in the developing countries 
3- With the rapid evolution of EBM a simple and 
explicit approach for the busy clinicians is needed.  
4- More collaboration between health care 
providers, medical industries and research groups.  
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